nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisinopril—Chest pain—Bleomycin—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Lisinopril—Alopecia—Vincristine—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Lisinopril—Back pain—Carmustine—lymphatic system cancer	0.00133	0.00133	CcSEcCtD
Lisinopril—Discomfort—Bleomycin—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Lisinopril—Mental disorder—Vincristine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Lisinopril—Chills—Mitoxantrone—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Lisinopril—Bladder pain—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Lisinopril—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Lisinopril—Alopecia—Mitoxantrone—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Lisinopril—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Lisinopril—Confusional state—Bleomycin—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Lisinopril—Vision blurred—Carmustine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Lisinopril—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Lisinopril—Tremor—Carmustine—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Lisinopril—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Lisinopril—Oedema—Bleomycin—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Lisinopril—Erythema—Mitoxantrone—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Lisinopril—Infection—Bleomycin—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Lisinopril—Anaemia—Carmustine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Lisinopril—Back pain—Vincristine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Lisinopril—Vomiting—Teniposide—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Lisinopril—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Lisinopril—Asthenia—Fludarabine—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Lisinopril—Rash—Teniposide—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Lisinopril—Dermatitis—Teniposide—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Lisinopril—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Lisinopril—Headache—Teniposide—lymphatic system cancer	0.00125	0.00125	CcSEcCtD
Lisinopril—Pruritus—Fludarabine—lymphatic system cancer	0.00124	0.00124	CcSEcCtD
Lisinopril—Back pain—Mitoxantrone—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Lisinopril—Leukopenia—Carmustine—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Lisinopril—Anorexia—Bleomycin—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Lisinopril—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Lisinopril—Anaemia—Vincristine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Lisinopril—Vision blurred—Mitoxantrone—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Lisinopril—Photosensitivity—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Lisinopril—Hypotension—Bleomycin—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Lisinopril—Diarrhoea—Fludarabine—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Lisinopril—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Lisinopril—Nausea—Teniposide—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Lisinopril—Anaemia—Mitoxantrone—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Lisinopril—Vertigo—Vincristine—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Lisinopril—Hepatic failure—Methotrexate—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Lisinopril—Leukopenia—Vincristine—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Lisinopril—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Lisinopril—Chest pain—Carmustine—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Lisinopril—Myalgia—Carmustine—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Lisinopril—Anxiety—Carmustine—lymphatic system cancer	0.00116	0.00116	CcSEcCtD
Lisinopril—Paraesthesia—Bleomycin—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Lisinopril—Malaise—Mitoxantrone—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Lisinopril—Dyspnoea—Bleomycin—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Lisinopril—Renal failure acute—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Lisinopril—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Lisinopril—Confusional state—Carmustine—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
Lisinopril—Oedema—Carmustine—lymphatic system cancer	0.00112	0.00112	CcSEcCtD
Lisinopril—Decreased appetite—Bleomycin—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Lisinopril—Myalgia—Vincristine—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Lisinopril—Cough—Mitoxantrone—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Lisinopril—Infection—Carmustine—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Lisinopril—Vomiting—Fludarabine—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Lisinopril—Rash—Fludarabine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Lisinopril—Dermatitis—Fludarabine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Lisinopril—Pain—Bleomycin—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Lisinopril—Thrombocytopenia—Carmustine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Lisinopril—Headache—Fludarabine—lymphatic system cancer	0.0011	0.0011	CcSEcCtD
Lisinopril—Tachycardia—Carmustine—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Lisinopril—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Lisinopril—Chest pain—Mitoxantrone—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Lisinopril—Myalgia—Mitoxantrone—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Lisinopril—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00109	0.00109	CcSEcCtD
Lisinopril—Anxiety—Mitoxantrone—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Lisinopril—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00108	0.00108	CcSEcCtD
Lisinopril—Discomfort—Mitoxantrone—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Lisinopril—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Lisinopril—Oedema—Vincristine—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Lisinopril—Anorexia—Carmustine—lymphatic system cancer	0.00107	0.00107	CcSEcCtD
Lisinopril—Infection—Vincristine—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Lisinopril—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00106	0.00106	CcSEcCtD
Lisinopril—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Lisinopril—Confusional state—Mitoxantrone—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Lisinopril—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Lisinopril—Hypotension—Carmustine—lymphatic system cancer	0.00105	0.00105	CcSEcCtD
Lisinopril—Oedema—Mitoxantrone—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Lisinopril—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Lisinopril—Nausea—Fludarabine—lymphatic system cancer	0.00104	0.00104	CcSEcCtD
Lisinopril—Infection—Mitoxantrone—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Lisinopril—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00103	0.00103	CcSEcCtD
Lisinopril—Shock—Mitoxantrone—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Lisinopril—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Lisinopril—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Lisinopril—Urticaria—Bleomycin—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Lisinopril—Anorexia—Vincristine—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Lisinopril—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00102	0.00102	CcSEcCtD
Lisinopril—Body temperature increased—Bleomycin—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Lisinopril—Insomnia—Carmustine—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Lisinopril—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Lisinopril—Irritability—Methotrexate—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Lisinopril—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00101	0.00101	CcSEcCtD
Lisinopril—Paraesthesia—Carmustine—lymphatic system cancer	0.001	0.001	CcSEcCtD
Lisinopril—Hypotension—Vincristine—lymphatic system cancer	0.000998	0.000998	CcSEcCtD
Lisinopril—Dyspnoea—Carmustine—lymphatic system cancer	0.000997	0.000997	CcSEcCtD
Lisinopril—Somnolence—Carmustine—lymphatic system cancer	0.000995	0.000995	CcSEcCtD
Lisinopril—Anorexia—Mitoxantrone—lymphatic system cancer	0.000991	0.000991	CcSEcCtD
Lisinopril—Ataxia—Methotrexate—lymphatic system cancer	0.000991	0.000991	CcSEcCtD
Lisinopril—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000973	0.000973	CcSEcCtD
Lisinopril—Decreased appetite—Carmustine—lymphatic system cancer	0.000973	0.000973	CcSEcCtD
Lisinopril—Hypotension—Mitoxantrone—lymphatic system cancer	0.000972	0.000972	CcSEcCtD
Lisinopril—Insomnia—Vincristine—lymphatic system cancer	0.000966	0.000966	CcSEcCtD
Lisinopril—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000966	0.000966	CcSEcCtD
Lisinopril—Paraesthesia—Vincristine—lymphatic system cancer	0.000959	0.000959	CcSEcCtD
Lisinopril—Constipation—Carmustine—lymphatic system cancer	0.000957	0.000957	CcSEcCtD
Lisinopril—Pain—Carmustine—lymphatic system cancer	0.000957	0.000957	CcSEcCtD
Lisinopril—Breast disorder—Methotrexate—lymphatic system cancer	0.000953	0.000953	CcSEcCtD
Lisinopril—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000949	0.000949	CcSEcCtD
Lisinopril—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000948	0.000948	CcSEcCtD
Lisinopril—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000944	0.000944	CcSEcCtD
Lisinopril—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000934	0.000934	CcSEcCtD
Lisinopril—Decreased appetite—Vincristine—lymphatic system cancer	0.000928	0.000928	CcSEcCtD
Lisinopril—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000927	0.000927	CcSEcCtD
Lisinopril—Somnolence—Mitoxantrone—lymphatic system cancer	0.000925	0.000925	CcSEcCtD
Lisinopril—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000922	0.000922	CcSEcCtD
Lisinopril—Feeling abnormal—Carmustine—lymphatic system cancer	0.000922	0.000922	CcSEcCtD
Lisinopril—Fatigue—Vincristine—lymphatic system cancer	0.000921	0.000921	CcSEcCtD
Lisinopril—Asthenia—Bleomycin—lymphatic system cancer	0.00092	0.00092	CcSEcCtD
Lisinopril—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000916	0.000916	CcSEcCtD
Lisinopril—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000915	0.000915	CcSEcCtD
Lisinopril—Pain—Vincristine—lymphatic system cancer	0.000913	0.000913	CcSEcCtD
Lisinopril—Constipation—Vincristine—lymphatic system cancer	0.000913	0.000913	CcSEcCtD
Lisinopril—Asthma—Methotrexate—lymphatic system cancer	0.000911	0.000911	CcSEcCtD
Lisinopril—Pruritus—Bleomycin—lymphatic system cancer	0.000907	0.000907	CcSEcCtD
Lisinopril—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000904	0.000904	CcSEcCtD
Lisinopril—Eosinophilia—Methotrexate—lymphatic system cancer	0.000902	0.000902	CcSEcCtD
Lisinopril—Fatigue—Mitoxantrone—lymphatic system cancer	0.000897	0.000897	CcSEcCtD
Lisinopril—Pancreatitis—Methotrexate—lymphatic system cancer	0.000893	0.000893	CcSEcCtD
Lisinopril—Constipation—Mitoxantrone—lymphatic system cancer	0.000889	0.000889	CcSEcCtD
Lisinopril—Pain—Mitoxantrone—lymphatic system cancer	0.000889	0.000889	CcSEcCtD
Lisinopril—Abdominal pain—Carmustine—lymphatic system cancer	0.000884	0.000884	CcSEcCtD
Lisinopril—Body temperature increased—Carmustine—lymphatic system cancer	0.000884	0.000884	CcSEcCtD
Lisinopril—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000873	0.000873	CcSEcCtD
Lisinopril—Pancytopenia—Methotrexate—lymphatic system cancer	0.000865	0.000865	CcSEcCtD
Lisinopril—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000857	0.000857	CcSEcCtD
Lisinopril—Dysuria—Methotrexate—lymphatic system cancer	0.000852	0.000852	CcSEcCtD
Lisinopril—Neutropenia—Methotrexate—lymphatic system cancer	0.000852	0.000852	CcSEcCtD
Lisinopril—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000851	0.000851	CcSEcCtD
Lisinopril—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000847	0.000847	CcSEcCtD
Lisinopril—Abdominal pain—Vincristine—lymphatic system cancer	0.000844	0.000844	CcSEcCtD
Lisinopril—Body temperature increased—Vincristine—lymphatic system cancer	0.000844	0.000844	CcSEcCtD
Lisinopril—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000839	0.000839	CcSEcCtD
Lisinopril—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000832	0.000832	CcSEcCtD
Lisinopril—Urticaria—Mitoxantrone—lymphatic system cancer	0.000826	0.000826	CcSEcCtD
Lisinopril—Hypersensitivity—Carmustine—lymphatic system cancer	0.000824	0.000824	CcSEcCtD
Lisinopril—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000822	0.000822	CcSEcCtD
Lisinopril—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000822	0.000822	CcSEcCtD
Lisinopril—Pneumonia—Methotrexate—lymphatic system cancer	0.000817	0.000817	CcSEcCtD
Lisinopril—Vomiting—Bleomycin—lymphatic system cancer	0.000815	0.000815	CcSEcCtD
Lisinopril—Depression—Methotrexate—lymphatic system cancer	0.00081	0.00081	CcSEcCtD
Lisinopril—Rash—Bleomycin—lymphatic system cancer	0.000808	0.000808	CcSEcCtD
Lisinopril—Dermatitis—Bleomycin—lymphatic system cancer	0.000807	0.000807	CcSEcCtD
Lisinopril—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000806	0.000806	CcSEcCtD
Lisinopril—Asthenia—Carmustine—lymphatic system cancer	0.000803	0.000803	CcSEcCtD
Lisinopril—Renal failure—Methotrexate—lymphatic system cancer	0.000799	0.000799	CcSEcCtD
Lisinopril—Hypersensitivity—Vincristine—lymphatic system cancer	0.000787	0.000787	CcSEcCtD
Lisinopril—Sweating—Methotrexate—lymphatic system cancer	0.000779	0.000779	CcSEcCtD
Lisinopril—Haematuria—Methotrexate—lymphatic system cancer	0.000775	0.000775	CcSEcCtD
Lisinopril—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000768	0.000768	CcSEcCtD
Lisinopril—Epistaxis—Methotrexate—lymphatic system cancer	0.000766	0.000766	CcSEcCtD
Lisinopril—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000766	0.000766	CcSEcCtD
Lisinopril—Asthenia—Vincristine—lymphatic system cancer	0.000766	0.000766	CcSEcCtD
Lisinopril—Diarrhoea—Carmustine—lymphatic system cancer	0.000766	0.000766	CcSEcCtD
Lisinopril—Nausea—Bleomycin—lymphatic system cancer	0.000761	0.000761	CcSEcCtD
Lisinopril—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000758	0.000758	CcSEcCtD
Lisinopril—Asthenia—Mitoxantrone—lymphatic system cancer	0.000746	0.000746	CcSEcCtD
Lisinopril—Dizziness—Carmustine—lymphatic system cancer	0.00074	0.00074	CcSEcCtD
Lisinopril—Diarrhoea—Vincristine—lymphatic system cancer	0.000731	0.000731	CcSEcCtD
Lisinopril—Hepatitis—Methotrexate—lymphatic system cancer	0.000729	0.000729	CcSEcCtD
Lisinopril—Pharyngitis—Methotrexate—lymphatic system cancer	0.000724	0.000724	CcSEcCtD
Lisinopril—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00072	0.00072	CcSEcCtD
Lisinopril—Urethral disorder—Methotrexate—lymphatic system cancer	0.000715	0.000715	CcSEcCtD
Lisinopril—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000712	0.000712	CcSEcCtD
Lisinopril—Vomiting—Carmustine—lymphatic system cancer	0.000711	0.000711	CcSEcCtD
Lisinopril—Dizziness—Vincristine—lymphatic system cancer	0.000706	0.000706	CcSEcCtD
Lisinopril—Rash—Carmustine—lymphatic system cancer	0.000705	0.000705	CcSEcCtD
Lisinopril—Dermatitis—Carmustine—lymphatic system cancer	0.000705	0.000705	CcSEcCtD
Lisinopril—Headache—Carmustine—lymphatic system cancer	0.000701	0.000701	CcSEcCtD
Lisinopril—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00069	0.00069	CcSEcCtD
Lisinopril—Tinnitus—Methotrexate—lymphatic system cancer	0.00068	0.00068	CcSEcCtD
Lisinopril—Vomiting—Vincristine—lymphatic system cancer	0.000679	0.000679	CcSEcCtD
Lisinopril—Rash—Vincristine—lymphatic system cancer	0.000673	0.000673	CcSEcCtD
Lisinopril—Dermatitis—Vincristine—lymphatic system cancer	0.000673	0.000673	CcSEcCtD
Lisinopril—Headache—Vincristine—lymphatic system cancer	0.000669	0.000669	CcSEcCtD
Lisinopril—Nausea—Carmustine—lymphatic system cancer	0.000665	0.000665	CcSEcCtD
Lisinopril—Angiopathy—Methotrexate—lymphatic system cancer	0.000662	0.000662	CcSEcCtD
Lisinopril—Vomiting—Mitoxantrone—lymphatic system cancer	0.000661	0.000661	CcSEcCtD
Lisinopril—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000657	0.000657	CcSEcCtD
Lisinopril—Rash—Mitoxantrone—lymphatic system cancer	0.000656	0.000656	CcSEcCtD
Lisinopril—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000655	0.000655	CcSEcCtD
Lisinopril—Chills—Methotrexate—lymphatic system cancer	0.000655	0.000655	CcSEcCtD
Lisinopril—Headache—Mitoxantrone—lymphatic system cancer	0.000652	0.000652	CcSEcCtD
Lisinopril—Alopecia—Methotrexate—lymphatic system cancer	0.000645	0.000645	CcSEcCtD
Lisinopril—Mental disorder—Methotrexate—lymphatic system cancer	0.000639	0.000639	CcSEcCtD
Lisinopril—Malnutrition—Methotrexate—lymphatic system cancer	0.000635	0.000635	CcSEcCtD
Lisinopril—Erythema—Methotrexate—lymphatic system cancer	0.000635	0.000635	CcSEcCtD
Lisinopril—Nausea—Vincristine—lymphatic system cancer	0.000634	0.000634	CcSEcCtD
Lisinopril—Dysgeusia—Methotrexate—lymphatic system cancer	0.000622	0.000622	CcSEcCtD
Lisinopril—Nausea—Mitoxantrone—lymphatic system cancer	0.000618	0.000618	CcSEcCtD
Lisinopril—Back pain—Methotrexate—lymphatic system cancer	0.000614	0.000614	CcSEcCtD
Lisinopril—Vision blurred—Methotrexate—lymphatic system cancer	0.000598	0.000598	CcSEcCtD
Lisinopril—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000589	0.000589	CcSEcCtD
Lisinopril—Anaemia—Methotrexate—lymphatic system cancer	0.000587	0.000587	CcSEcCtD
Lisinopril—Malaise—Methotrexate—lymphatic system cancer	0.000573	0.000573	CcSEcCtD
Lisinopril—Vertigo—Methotrexate—lymphatic system cancer	0.000571	0.000571	CcSEcCtD
Lisinopril—Leukopenia—Methotrexate—lymphatic system cancer	0.000568	0.000568	CcSEcCtD
Lisinopril—Cough—Methotrexate—lymphatic system cancer	0.000554	0.000554	CcSEcCtD
Lisinopril—Myalgia—Methotrexate—lymphatic system cancer	0.000541	0.000541	CcSEcCtD
Lisinopril—Arthralgia—Methotrexate—lymphatic system cancer	0.000541	0.000541	CcSEcCtD
Lisinopril—Chest pain—Methotrexate—lymphatic system cancer	0.000541	0.000541	CcSEcCtD
Lisinopril—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000537	0.000537	CcSEcCtD
Lisinopril—Discomfort—Methotrexate—lymphatic system cancer	0.000534	0.000534	CcSEcCtD
Lisinopril—Confusional state—Methotrexate—lymphatic system cancer	0.000523	0.000523	CcSEcCtD
Lisinopril—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000518	0.000518	CcSEcCtD
Lisinopril—Infection—Methotrexate—lymphatic system cancer	0.000515	0.000515	CcSEcCtD
Lisinopril—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000507	0.000507	CcSEcCtD
Lisinopril—Skin disorder—Methotrexate—lymphatic system cancer	0.000503	0.000503	CcSEcCtD
Lisinopril—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000501	0.000501	CcSEcCtD
Lisinopril—Anorexia—Methotrexate—lymphatic system cancer	0.000494	0.000494	CcSEcCtD
Lisinopril—Hypotension—Methotrexate—lymphatic system cancer	0.000484	0.000484	CcSEcCtD
Lisinopril—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000472	0.000472	CcSEcCtD
Lisinopril—Insomnia—Methotrexate—lymphatic system cancer	0.000469	0.000469	CcSEcCtD
Lisinopril—Paraesthesia—Methotrexate—lymphatic system cancer	0.000465	0.000465	CcSEcCtD
Lisinopril—Dyspnoea—Methotrexate—lymphatic system cancer	0.000462	0.000462	CcSEcCtD
Lisinopril—Somnolence—Methotrexate—lymphatic system cancer	0.000461	0.000461	CcSEcCtD
Lisinopril—Dyspepsia—Methotrexate—lymphatic system cancer	0.000456	0.000456	CcSEcCtD
Lisinopril—Decreased appetite—Methotrexate—lymphatic system cancer	0.000451	0.000451	CcSEcCtD
Lisinopril—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000447	0.000447	CcSEcCtD
Lisinopril—Fatigue—Methotrexate—lymphatic system cancer	0.000447	0.000447	CcSEcCtD
Lisinopril—Pain—Methotrexate—lymphatic system cancer	0.000443	0.000443	CcSEcCtD
Lisinopril—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000427	0.000427	CcSEcCtD
Lisinopril—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000424	0.000424	CcSEcCtD
Lisinopril—Urticaria—Methotrexate—lymphatic system cancer	0.000412	0.000412	CcSEcCtD
Lisinopril—Abdominal pain—Methotrexate—lymphatic system cancer	0.00041	0.00041	CcSEcCtD
Lisinopril—Body temperature increased—Methotrexate—lymphatic system cancer	0.00041	0.00041	CcSEcCtD
Lisinopril—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000382	0.000382	CcSEcCtD
Lisinopril—Asthenia—Methotrexate—lymphatic system cancer	0.000372	0.000372	CcSEcCtD
Lisinopril—Pruritus—Methotrexate—lymphatic system cancer	0.000367	0.000367	CcSEcCtD
Lisinopril—Diarrhoea—Methotrexate—lymphatic system cancer	0.000355	0.000355	CcSEcCtD
Lisinopril—Dizziness—Methotrexate—lymphatic system cancer	0.000343	0.000343	CcSEcCtD
Lisinopril—Vomiting—Methotrexate—lymphatic system cancer	0.00033	0.00033	CcSEcCtD
Lisinopril—Rash—Methotrexate—lymphatic system cancer	0.000327	0.000327	CcSEcCtD
Lisinopril—Dermatitis—Methotrexate—lymphatic system cancer	0.000326	0.000326	CcSEcCtD
Lisinopril—Headache—Methotrexate—lymphatic system cancer	0.000325	0.000325	CcSEcCtD
Lisinopril—Nausea—Methotrexate—lymphatic system cancer	0.000308	0.000308	CcSEcCtD
